Teva Pharmaceutical beats Q3 top and bottom line estimates, raises outlook
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
- Teva Pharmaceutical press release (NYSE:TEVA): Q3 Non-GAAP EPS of $0.69 beats by $0.03.
- Revenue of $4.3B (+11.7% Y/Y) beats by $170M.
-
Outlook for 2024 Non-GAAP Results
$ billions, except EPS or as noted
November 2024 Outlook
July 2024 Outlook
February 2024 Outlook
Revenues*
$16.1 – $16.5
$16.0 – $16.4
$15.7 – $16.3
AUSTEDO ($m)*
~1,600
~1,600
~1,500
AJOVY ($m)*
~500
~500
~500
UZEDY ($m)*
~100
~80
~80
COPAXONE ($m)*
~500
~450
~400
Operating Income
4.2 – 4.5
4.1 – 4.5
4.0 – 4.5
Adjusted EBITDA
4.7 – 5.0
4.6 – 5.0
4.5 – 5.0
Finance Expenses ($m)
~1,000
~1,000
~1,000
Tax Rate
14% – 17%
14% – 17%
14% – 17%
Diluted EPS ($)
2.40 – 2.50
2.30 – 2.50
2.20 – 2.50
Free Cash Flow**
1.7 – 2.0
1.7 – 2.0
1.7 – 2.0
CAPEX*
~0.5
~0.5
~0.5